Sigma‐1 receptor attenuates osteoclastogenesis by promoting ER‐associated degradation of SERCA2

Abstract Sigma‐1 receptor (Sigmar1) is a specific chaperone located in the mitochondria‐associated endoplasmic reticulum membrane (MAM) and plays a role in several physiological processes. However, the role of Sigmar1 in bone homeostasis remains unknown. Here, we show that mice lacking Sigmar1 exhib...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoan Wei, Zeyu Zheng, Zhenhua Feng, Lin Zheng, Siyue Tao, Bingjie Zheng, Bao Huang, Xuyang Zhang, Junhui Liu, Yilei Chen, Wentian Zong, Zhi Shan, Shunwu Fan, Jian Chen, Fengdong Zhao
Format: Article
Language:English
Published: Springer Nature 2022-05-01
Series:EMBO Molecular Medicine
Subjects:
Online Access:https://doi.org/10.15252/emmm.202115373
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850204150771482624
author Xiaoan Wei
Zeyu Zheng
Zhenhua Feng
Lin Zheng
Siyue Tao
Bingjie Zheng
Bao Huang
Xuyang Zhang
Junhui Liu
Yilei Chen
Wentian Zong
Zhi Shan
Shunwu Fan
Jian Chen
Fengdong Zhao
author_facet Xiaoan Wei
Zeyu Zheng
Zhenhua Feng
Lin Zheng
Siyue Tao
Bingjie Zheng
Bao Huang
Xuyang Zhang
Junhui Liu
Yilei Chen
Wentian Zong
Zhi Shan
Shunwu Fan
Jian Chen
Fengdong Zhao
author_sort Xiaoan Wei
collection DOAJ
description Abstract Sigma‐1 receptor (Sigmar1) is a specific chaperone located in the mitochondria‐associated endoplasmic reticulum membrane (MAM) and plays a role in several physiological processes. However, the role of Sigmar1 in bone homeostasis remains unknown. Here, we show that mice lacking Sigmar1 exhibited severe osteoporosis in an ovariectomized model. In contrast, overexpression of Sigmar1 locally alleviated the osteoporosis phenotype. Treatment with Sigmar1 agonists impaired both human and mice osteoclast formation in vitro. Mechanistically, SERCA2 was identified to interact with Sigmar1 based on the immunoprecipitation‐mass spectrum (IP‐MS) and co‐immunoprecipitation (co‐IP) assays, and Q615 of SERCA2 was confirmed to be the critical residue for their binding. Furthermore, Sigmar1 promoted SERCA2 degradation through Hrd1/Sel1L‐dependent ER‐associated degradation (ERAD). Ubiquitination of SERCA2 at K460 and K541 was responsible for its proteasomal degradation. Consequently, inhibition of SERCA2 impeded Sigmar1 deficiency enhanced osteoclastogenesis. Moreover, we found that dimemorfan, an FDA‐approved Sigmar1 agonist, effectively rescued bone mass in various established bone‐loss models. In conclusion, Sigmar1 is a negative regulator of osteoclastogenesis, and activation of Sigmar1 by dimemorfan may be a potential treatment for osteoporosis in clinical practice.
format Article
id doaj-art-2b082e75e2a845d9a094c2a620d7baef
institution OA Journals
issn 1757-4676
1757-4684
language English
publishDate 2022-05-01
publisher Springer Nature
record_format Article
series EMBO Molecular Medicine
spelling doaj-art-2b082e75e2a845d9a094c2a620d7baef2025-08-20T02:11:21ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842022-05-0114711810.15252/emmm.202115373Sigma‐1 receptor attenuates osteoclastogenesis by promoting ER‐associated degradation of SERCA2Xiaoan Wei0Zeyu Zheng1Zhenhua Feng2Lin Zheng3Siyue Tao4Bingjie Zheng5Bao Huang6Xuyang Zhang7Junhui Liu8Yilei Chen9Wentian Zong10Zhi Shan11Shunwu Fan12Jian Chen13Fengdong Zhao14Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineDepartment of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of MedicineAbstract Sigma‐1 receptor (Sigmar1) is a specific chaperone located in the mitochondria‐associated endoplasmic reticulum membrane (MAM) and plays a role in several physiological processes. However, the role of Sigmar1 in bone homeostasis remains unknown. Here, we show that mice lacking Sigmar1 exhibited severe osteoporosis in an ovariectomized model. In contrast, overexpression of Sigmar1 locally alleviated the osteoporosis phenotype. Treatment with Sigmar1 agonists impaired both human and mice osteoclast formation in vitro. Mechanistically, SERCA2 was identified to interact with Sigmar1 based on the immunoprecipitation‐mass spectrum (IP‐MS) and co‐immunoprecipitation (co‐IP) assays, and Q615 of SERCA2 was confirmed to be the critical residue for their binding. Furthermore, Sigmar1 promoted SERCA2 degradation through Hrd1/Sel1L‐dependent ER‐associated degradation (ERAD). Ubiquitination of SERCA2 at K460 and K541 was responsible for its proteasomal degradation. Consequently, inhibition of SERCA2 impeded Sigmar1 deficiency enhanced osteoclastogenesis. Moreover, we found that dimemorfan, an FDA‐approved Sigmar1 agonist, effectively rescued bone mass in various established bone‐loss models. In conclusion, Sigmar1 is a negative regulator of osteoclastogenesis, and activation of Sigmar1 by dimemorfan may be a potential treatment for osteoporosis in clinical practice.https://doi.org/10.15252/emmm.202115373ER‐associated degradationdimemorfanosteoporosisSERCA2Sigma‐1 receptor
spellingShingle Xiaoan Wei
Zeyu Zheng
Zhenhua Feng
Lin Zheng
Siyue Tao
Bingjie Zheng
Bao Huang
Xuyang Zhang
Junhui Liu
Yilei Chen
Wentian Zong
Zhi Shan
Shunwu Fan
Jian Chen
Fengdong Zhao
Sigma‐1 receptor attenuates osteoclastogenesis by promoting ER‐associated degradation of SERCA2
EMBO Molecular Medicine
ER‐associated degradation
dimemorfan
osteoporosis
SERCA2
Sigma‐1 receptor
title Sigma‐1 receptor attenuates osteoclastogenesis by promoting ER‐associated degradation of SERCA2
title_full Sigma‐1 receptor attenuates osteoclastogenesis by promoting ER‐associated degradation of SERCA2
title_fullStr Sigma‐1 receptor attenuates osteoclastogenesis by promoting ER‐associated degradation of SERCA2
title_full_unstemmed Sigma‐1 receptor attenuates osteoclastogenesis by promoting ER‐associated degradation of SERCA2
title_short Sigma‐1 receptor attenuates osteoclastogenesis by promoting ER‐associated degradation of SERCA2
title_sort sigma 1 receptor attenuates osteoclastogenesis by promoting er associated degradation of serca2
topic ER‐associated degradation
dimemorfan
osteoporosis
SERCA2
Sigma‐1 receptor
url https://doi.org/10.15252/emmm.202115373
work_keys_str_mv AT xiaoanwei sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2
AT zeyuzheng sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2
AT zhenhuafeng sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2
AT linzheng sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2
AT siyuetao sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2
AT bingjiezheng sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2
AT baohuang sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2
AT xuyangzhang sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2
AT junhuiliu sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2
AT yileichen sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2
AT wentianzong sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2
AT zhishan sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2
AT shunwufan sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2
AT jianchen sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2
AT fengdongzhao sigma1receptorattenuatesosteoclastogenesisbypromotingerassociateddegradationofserca2